Format

Send to:

Choose Destination
See comment in PubMed Commons below
Acta Psychiatr Scand. 2000 Mar;101(3):218-25.

A placebo-controlled comparison of zotepine versus chlorpromazine in patients with acute exacerbation of schizophrenia.

Author information

  • 1Department of Mental Health, The Queen's University of Belfast, Northern Ireland.

Abstract

OBJECTIVE:

The aim of this study was to evaluate the efficacy of zotepine in the treatment of acute episodes of schizophrenia.

METHOD:

Patients with acute exacerbation of schizophrenia (DSM-III-R criteria; n = 158) were allocated on a random, double-blind basis to receive zotepine (150 or 300 mg/day), chlorpromazine (300 or 600 mg/day) or placebo for 8 weeks. Symptoms were assessed on the BPRS, SANS and CGI scales at baseline and weeks 1, 2, 4, 6 and 8 and patients were assessed at these times for adverse effects. Analysis was by analysis of variance on the intent-to-treat population, with last observation carried forward.

RESULTS:

Mean BPRS scores improved statistically significantly more with zotepine than chlorpromazine (point estimate of difference -12.4, 95% CI -18.3 to -6.5) or placebo (point estimate of difference -12.7, 95% CI -18.6 to -6.8). Zotepine produced significantly fewer extrapyramidal symptoms (EPS) than chlorpromazine.

CONCLUSION:

Zotepine is an effective antipsychotic with low propensity for EPS.

Comment in

PMID:
10721870
[PubMed - indexed for MEDLINE]
PubMed Commons home

PubMed Commons

0 comments
How to join PubMed Commons

    Supplemental Content

    Full text links

    Icon for Blackwell Publishing
    Loading ...
    Write to the Help Desk